Interleukin‐6 and the Risk of Adverse Outcomes in Patients After an Acute Coronary Syndrome: Observations From the SOLID‐TIMI 52 (Stabilization of Plaque Using Darapladib—Thrombolysis in Myocardial Infarction 52) Trial
暂无分享,去创建一个
E. Braunwald | C. Cannon | D. Morrow | C. Bode | J. Hochman | M. O’Donoghue | Christina L. Fanola | M. Lukas | Erica L. Goodrich | P. Jarolím
[1] P. Libby,et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.
[2] Gurkirpal Singh,et al. Interleukin 6 Inhibition and Coronary Artery Disease in a High‐Risk Population: A Prospective Community‐Based Clinical Study , 2017, Journal of the American Heart Association.
[3] B. Amundsen,et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. , 2016, European heart journal.
[4] A. Parkhomenko,et al. Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. , 2016, JAMA.
[5] Solid-Timi Investigators. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014 .
[6] Daniel F. Freitag,et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. , 2014, European heart journal.
[7] Poonam Kothari,et al. IL-6–Mediated Induction of Matrix Metalloproteinase-9 Is Modulated by JAK-Dependent IL-10 Expression in Macrophages , 2014, The Journal of Immunology.
[8] V. Hasselblad,et al. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. , 2013, International journal of cardiology.
[9] P. Libby,et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. , 2013, American heart journal.
[10] M. Nahrendorf,et al. Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure , 2013, Science.
[11] V. Hasselblad,et al. The study of LoSmapimod treatment on inflammation and InfarCtSizE (SOLSTICE): design and rationale. , 2012, American heart journal.
[12] John Pernow,et al. Identification and Predictive Value of Interleukin-6+ Interleukin-10+ and Interleukin-6− Interleukin-10+ Cytokine Patterns in ST-Elevation Acute Myocardial Infarction , 2012, Circulation research.
[13] Charles P. Lin,et al. Myocardial infarction accelerates atherosclerosis , 2012, Nature.
[14] Mark Woodward,et al. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies , 2012 .
[15] E. Braunwald,et al. Study design and rationale for the Stabilization of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction (SOLID-TIMI 52) trial in patients after an acute coronary syndrome. , 2011, American heart journal.
[16] Sawa Kostin,et al. Fibrosis in endstage human heart failure: severe changes in collagen metabolism and MMP/TIMP profiles. , 2011, International journal of cardiology.
[17] P. Libby,et al. Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.
[18] Akiko Maehara,et al. A prospective natural-history study of coronary atherosclerosis. , 2011, The New England journal of medicine.
[19] M. Hersberger,et al. Inflammatory Markers at the Site of Ruptured Plaque in Acute Myocardial Infarction: Locally Increased Interleukin-6 and Serum Amyloid A but Decreased C-Reactive Protein , 2005, Circulation.
[20] C. Trautwein,et al. Impact of Interleukin-6 on Plaque Development and Morphology in Experimental Atherosclerosis , 2004, Circulation.
[21] A. Siegbahn,et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. , 2001, JAMA.
[22] A. Siegbahn,et al. Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease. , 2000, The New England journal of medicine.
[23] P. Ridker,et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.
[24] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[25] S. Humphries,et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.
[26] E. Antman,et al. C-Reactive Protein Is a Potent Predictor of Mortality Independently of and in Combination With Troponin T in Acute Coronary Syndromes: A TIMI 11A Substudy , 1998 .
[27] J V Castell,et al. Interleukin-6 and the acute phase response. , 1990, The Biochemical journal.
[28] Dylan L. Steen,et al. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. , 2014, JAMA.
[29] E. Barrett-Connor,et al. Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). , 2007, The American journal of cardiology.
[30] G. Pasterkamp,et al. Multiple complex coronary plaques in patients with acute myocardial infarction. , 2001, The New England journal of medicine.
[31] E. Antman,et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis in Myocardial Infarction. , 1998, Journal of the American College of Cardiology.